MRNA241227P53000
- 12.60
- +1.20+10.53%
Moderna Newsroom
Moderna Options Spot-On: On December 26th, 149.21K Contracts Were Traded, With 640.82K Open Interest
Unusual Options Activity: MSTR, HIMS and Others Attract Market Bets, MSTR V/OI Ratio Reaches 35.0
Moderna Options Spot-On: On December 24th, 31,734 Contracts Were Traded, With 634.47K Open Interest
Moderna Options Spot-On: On December 23rd, 78,770 Contracts Were Traded, With 730.7K Open Interest
2024's Top and Bottom Nasdaq-100 Performers Includes NVDA, APP, INTC, MRNA, and More
Moderna Stock Down 39% in Three Months: Buy the Dip or Wait?
S&P 500: 2024 Stars, Flops, and What's Hot for 2025
SA Asks: Which Big Pharmas Are Likely to Announce Big M&A Deals?
Daily short sale tracking: Palantir's short volume increased by 51 million, with a short sale ratio of 23%
Weekly Buzz: It was a rough week just before the Winter Solstice
Catalyst Watch: Labor Pains for Amazon & Starbucks, Nasdaq Call-up for MicroStrategy and Pony AI Ratings
Friday Opens With Falling Prices, but Market Turns Around | Live Stock
Is Moderna Stock a Buy?
Moderna Options Spot-On: On December 19th, 214.79K Contracts Were Traded, With 705.56K Open Interest
Unusual Options Activity: SLB, Z and Others Attract Market Bets, SLB V/OI Ratio Reaches 375.0
Personalis Rallies Following $50 Million Investment From Merck, Extended Agreement With Moderna
Merck Buys $50 Million of Personalis Stock
Express News | Personalis Signs Multi-Year Extension With Moderna To Utilize Its ImmunoID NeXT Platform And Technology For V940/mRNA-4157
Express News | Personalis Inc: Merck Has Agreed to Purchase $50 Mln of Personalis Common Stock in a Private Placement at a Price of $3.56 per Share
Express News | Personalis Advances Business Strategy With Investment From Merck and Extends Collaboration With Moderna